Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. H 168 68
2. H 168-68
3. H 16868
4. Magnesium, Omeprazole
5. Omeprazole
6. Omeprazole Magnesium
7. Omeprazole Sodium
8. Prilosec
9. Sodium, Omeprazole
1. Omeprazole Sodium
2. Losec Sodium
3. H 168/68 Sodium
4. 95510-70-6
5. Omeprazole Sodium [usan]
6. 161796-78-7
7. Omeprazole (as Sodium)
8. Kv03yz6qlw
9. 95510-70-6 (sodium)
10. Andra
11. Omeprazole Sodium (usan)
12. 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, Sodium Salt
13. 1h-benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
14. (s)-omeprazole Sodium
15. Esomeprazole Sodium Salt
16. Sompraz
17. Sodium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
18. Unii-kv03yz6qlw
19. Losec Sodium (tn)
20. Esomeprazole Sodium (nexium)
21. Omeprazole Sodium [jan]
22. Chembl2105294
23. H-168/68 Sodium
24. Chebi:31934
25. Omeprazole Sodium [mart.]
26. Hms3651e16
27. Omeprazole Sodium [who-dd]
28. Bcp23377
29. Esomeprazole Sodium (nexium I.v.)
30. Ac-403
31. S5658
32. Akos024255604
33. Bcp9000660
34. Omeprazole Sodium [ep Monograph]
35. Bcp0726000228
36. Sw219428-1
37. D01207
38. Ab01274809-01
39. Q27282459
40. Sodium 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-3ah-benzimidazole
1. Omeprazole Sodium Hydrate
Molecular Weight | 367.4 g/mol |
---|---|
Molecular Formula | C17H18N3NaO3S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 367.09665690 g/mol |
Monoisotopic Mass | 367.09665690 g/mol |
Topological Polar Surface Area | 81.5 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 459 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Esomeprazole sodium |
Drug Label | The active ingredient in esomeprazole sodium for injection is (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isome... |
Active Ingredient | Esomeprazole sodium |
Dosage Form | Injectable |
Route | Intravenous |
Strength | eq 20mg base/vial; eq 40mg base/vial |
Market Status | Prescription |
Company | Sun Pharma Global |
2 of 4 | |
---|---|
Drug Name | Nexium |
PubMed Health | Esomeprazole |
Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
Drug Label | The active ingredient in NEXIUM (esomeprazole magnesium) Delayed-Release Capsules and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole... |
Active Ingredient | Esomeprazole magnesium |
Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
Route | Oral |
Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
Market Status | Prescription |
Company | Astrazeneca |
3 of 4 | |
---|---|
Drug Name | Esomeprazole sodium |
Drug Label | The active ingredient in esomeprazole sodium for injection is (S)-5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole sodium, a proton pump inhibitor that inhibits gastric acid secretion. Esomeprazole is the S-isome... |
Active Ingredient | Esomeprazole sodium |
Dosage Form | Injectable |
Route | Intravenous |
Strength | eq 20mg base/vial; eq 40mg base/vial |
Market Status | Prescription |
Company | Sun Pharma Global |
4 of 4 | |
---|---|
Drug Name | Nexium |
PubMed Health | Esomeprazole |
Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
Drug Label | The active ingredient in NEXIUM (esomeprazole magnesium) Delayed-Release Capsules and NEXIUM (esomeprazole magnesium) For Delayed-Release Oral Suspension is bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole... |
Active Ingredient | Esomeprazole magnesium |
Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
Route | Oral |
Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
Market Status | Prescription |
Company | Astrazeneca |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?